Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
76144-81-5
Molecular formula
C6H14N2O2
Molecular weight
146.19 g/mol
Drug class
Cardiometabolic agentgamma-butyrobetaine hydroxylase and carnitine-transport modulator
Mechanism of action
Inhibits gamma-butyrobetaine hydroxylase and the OCTN2 carnitine transporter, reducing endogenous L-carnitine availability and limiting mitochondrial uptake and beta-oxidation of long-chain fatty acids. This shifts cellular energy metabolism toward glucose oxidation and may reduce oxygen consumption under ischaemic conditions.
Indications / reported uses
Used in selected countries as an adjunctive cardiometabolic treatment for ischaemic heart disease and related circulatory disorders; it is not approved in the United States and is not a universally authorised standard therapy.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Meldonium Environmental Risk Assessment (ERA) (the Meldonium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.